Mistletoe
Mistletoe is widely prescribed
immune therapy used in treating cancer patients in Europe both as concurrent
therapy with chemotherapy and as adjuvant treatment. Subcutaneous injections of
mistletoe lectins have been studied in over 25 cancer clinical trials in
Europe, Russia and other countries, but thus far not in the U.S. The bulk of
the data suggests anti-tumor activity across several tumor types. In Europe,
mistletoe remains one the most extensively studied herbal preparations with
over 1,000 published scientific articles.
Mistletoe products are sold as
Iscador, Helixor, Abnoba viscum, Isorel, Eurixor, and Plenosol.
Preclinical studies have shown
cytotoxic, carcinostatic and immunomodulatory effects both in vitro and in vivo
on a variety of tumor cells.
Clinical studies have also shown
cytotoxic effects of mistletoe over various tumor types. Most of these studies
report improvements in response, survival and/or 'quality of life' although
many of these reports were of less than ideal designs (i.e. small studies, lack
of randomization or lack of appropriate assessment of clinical improvement).
Safety
Data have shown mistletoe has low
toxicity and it is safe for use in cancer patients. In fact, mistletoe is
widely used as anti-cancer therapy in Europe, particularly in Germany, where
most of the research has been carried out.
Although mistletoe extracts have
yet to undergo large randomized clinical investigation in the treatment of
cancer in the United States, this botanical has been extensively researched in
Europe where is often prescribed as a botanical for anti-cancer treatment.
http://depts.washington.edu/integonc/clinicians/act/mistletoe.shtml
Tiada ulasan:
Catat Ulasan
Nota: Hanya ahli blog ini sahaja yang boleh mencatat ulasan.